This website uses cookies
Read our Privacy policy and Terms of use for more information.
Long Form Content
Oct 23, 2025
•
11 min read
🧬 Alkermes drops $2.1B on Avadel Pharma acquisition (excessive sleepiness therapeutics), Electra's $183M Series C powering rare inflammatory disease drug development, Flagship Pioneering launches Expedition Medicines with $50M to apply AI and covalent chemistry in cancer and immune diseases drug development, Sanofi's efdoralprin alfa meets Ph2 goals in alpha-1 antitrypsin deficiency, Novavax transfers Maryland HQ lease to AstraZeneca for $59.8M, AstraZeneca + Amgen's Tezspire lands EU approval in chronic rhinosinusitis with nasal polyps, Regeneron settles Eylea patent dispute with Celltrion - clearing biosimilar launch for December 2026
Oct 22, 2025
8 min read
🧬 Elevara Medicines launches with $70M + an in-licensed Ph2 ready asset, Axial Tx rebrands as Vertero Tx + $20M Series D, Chemify's $50M Series B to "digitize chemistry", AbbVie's Rinvoq beats Humira in Ph3 rheumatoid arthritis trial, Takeda, + Innovent Biologics partner on late-stage oncology medicines for solid tumors, Samsung Bioepis + Phrontline Biopharma partner on dual-payload ADC development involving undisclosed financials
Oct 21, 2025
🧬 Roche's anti-cancer anti-CD20 lands lupus approval from FDA, Glaukos Epioxa lands FDA approval for rare eye disease, rumor mill sends Nektar Tx shares skyward over potential Eli Lilly acquisition, Kelun-Biotech unveils impressive lung cancer survival data for asset out-licensed to Merck & Co. outside Greater China, IDEAYA Biosciences' touts positive Ph2 data for darovasertib in eye cancer, Alto Neuroscience shares double after announcing plans to "accelerate" investigational depression med development after positive FDA meeting, Merck & Co. breaks ground on $3B Virginia small molecule plant
Oct 20, 2025
10 min read
🧬 Roche's Chugai's up to $1.1B deal with Rani Tx to make oral versions of injectables, Amgen + AstraZeneca nab Tezspire label extension into chronic rhinosinusitis with nasal polyps, Merck & Co. Keytruda + Pfizer & Astellas' Padcev delivers stellar Ph3 bladder cancer data, Roche signs up to $1.45B ADC deal with Hansoh Pharmaceutical, FDA hands out first batch of Commissioner’s Priority Vouchers
Oct 17, 2025
🧬 Veradermics' $150M Series C for hair regrowth (the second $100+ hair-focused biotech raise this week), Kite Pharma goes deeper on in-vivo with up to $1.64B deal with Pregene Biotech, Dianthus Tx's up to $1B deal for Nanjing Leads Biolabs' bispecific, Adcytherix's $122M Series A powering ADC ambitions, Aicuris preps FDA filing after Ph3 win in treating immunocompromised patients with herpes, Merck & Co. delivers another Keytruda win with statistically significant OS benefit in platinum resistant ovarian cancer
Oct 16, 2025
🧬 Tubulis' $361M Series C for ovarian + lung cancer ADC development, Pelage Pharmaceuticals closes $120M Series B targeting hair loss, Novo in-licenses Omeros's rare blood + kidney disease hopeful for up to $2.1B, Boehringer Ingelheim in-licenses ADC asset from AimedBio for up to $991M, Eli Lilly touts pair of Ph3 results for potential oral "foundational treatment" for type 2 diabetes, AstraZeneca drops $445M more on Texas-based Lokelma production site
Oct 15, 2025
13 min read
🧬 Kailera's $600M Series B (fueling obesity ambitions), Excellergy launches with $70 to control allergic reaction diseases "at the source", LTS Lohmann buys up US-based Renaissance Lakewood CDMO, Pfizer's Seagen acquisition continues delivering with another Ph3 win in HER2-positive breast cancer, Takeda + Nabla deepen partnership with up to $1B on the table (focused on AI-powered biologics discovery), Teva Pharmaceuticals + Medincell score FDA approval for once-monthly bipolar treatment
Oct 13, 2025
🧬 BMS dives further into in-vivo cell therapy with $1.5B Orbital Tx buy, AstraZeneca agress to MFN pricing + joins TrumpRx, Ypsomed to build $248M NC-based manufacturing facility, J&J potentially buying Protagonist Tx in rumored well above $4B market value
Oct 10, 2025
🧬 Novo Nordisk to buy Akero Tx for $4.7B, AstraZeneca kicks off construction on $4.5B Virginia-based API plant, Ascenta Capital announces inagurual $325M fund focused on platform biotech, Ono Pharma + Bristol Myers Squibb's EP4 antagonist touts positive Ph2 data in gastric cancer, AstraZeneca + Turbine partner on ADC discovery via experimental virtualization at scale, AviadoBio in-licenses rare eye disease gene therapy from China's UgeneX Therapeutics for up to $413M, Expedition Tx raises $165M Series A for DPP1 inhibitor in treating COPD
Oct 9, 2025
9 min read
🧬 Nilo Tx launches with $101M to target the "body-brain circuit", Sanofi touts positive Ph2 radiopharma data in neuroendocrine tumors, Sanofi + BenchSci partner on AI-powered preclinical research platform, TransCode acquires Polynoma + secures $25M funding to advance phase 3 cancer vaccine, Regeneron's Libtayo PD-1 inhibitor lands FDA adjuvant therapy approval in squamous cell carcinoma, UK government considers raising NICE cost-effectiveness threshold to increase NHS drug spending
Oct 8, 2025
🧬 Soufflé Therapeutics rises to the occasion with $200M for siRNA therapies, MapLight seeks $227M IPO for neuropsychiatric drug development portfolio, FDA approves Boehringer Ingelheim's jascayd PDE4 inhibitor in idiopathic pulmonary fibrosis, GEMMABio launches RareTx spin-out focused on ultra-rare orphan diseases, OXB purchases US viral vector site from National Resilience, Boehringer + MOLCURE AI-powered mAbs discovery and development pact, BlueRock Tx touts positive Ph1 cell therapy data in Parkinson's
Oct 7, 2025
🧬 TCG Crossover raises $1.3B third fund focused on biotech + life sciences, AstraZeneca + Daiichi Sankyo's Datroway shows survival benefit vs chemotherapy in Ph3 triple-negative breast cancer trial, Trogenix's "Trojan Horse"-tech for cancer biotech lands £70M Series A, AstraZeneca + Algen sign up to $555M AI-powered drug discovery partnership, Chiesi + Arbor up to $2.1B rare disease partnership, Eli Lilly to invest up to $1B in Indian-based CDMO partnerships
